{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-008182","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.663731+00:00","generated_at":"2026-05-16T20:46:42.917865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic","bullets":["Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.","Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.","Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.","In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.","Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-008182","json":"https://secwatch.observer/filing/0001477932-25-008182.json","markdown":"https://secwatch.observer/filing/0001477932-25-008182.md","text":"https://secwatch.observer/filing/0001477932-25-008182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/0001477932-25-008182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:46:42.917865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}